Tenormin and Jakafi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tenormin (atenolol) and Jakafi (ruxolitinib phosphate). Common drug interactions include nausea among females and abdominal pain among males.

The phase IV clinical study analyzes what interactions people have when they take Tenormin and Jakafi. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Tenormin?

Tenormin has active ingredients of atenolol. It is often used in high blood pressure. eHealthMe is studying from 20,474 Tenormin users. Check the latest studies of Tenormin.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

39 people who take Tenormin and Jakafi together, and have interactions are studied.

What are the common drug interactions of Tenormin and Jakafi, by gender? *:

female:

Nausea (feeling of having an urge to vomit)
Alopecia (absence of hair from areas of the body)
Constipation
Cough
Dizziness
Dyspnoea exertional (breathlessness or shortness of breath)
Haematocrit increased
Anaemia (lack of blood)
Platelet count decreased
Thrombocytopenia (decrease of platelets in blood)

male:

Abdominal pain
Abdominal distension
Epistaxis (bleed from the nose)
Fatigue (feeling of tiredness)
Headache (pain in head)
Malaise (a feeling of general discomfort or uneasiness)
Memory impairment
Night sweats (sweating in night)
Weight decreased
White blood cell count decreased

What are the common drug interactions of Tenormin and Jakafi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Abdominal pain
Anaemia (lack of blood)
Epistaxis (bleed from the nose)
Fatigue (feeling of tiredness)
Headache (pain in head)
Malaise (a feeling of general discomfort or uneasiness)
Memory impairment
Night sweats (sweating in night)
Weight decreased
White blood cell count decreased

60+:

Nausea (feeling of having an urge to vomit)
Alopecia (absence of hair from areas of the body)
Platelet count decreased
Thrombocytopenia (decrease of platelets in blood)
Alanine aminotransferase increased
Blood bilirubin increased
Cellulitis (infection under the skin)
Dyspnoea (difficult or laboured respiration)
Injury
Myalgia (muscle pain)

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 24 people, 61.54%
Pain: 12 people, 30.77%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 11 people, 28.21%
Sinusitis (inflammation of sinus): 10 people, 25.64%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 8 people, 20.51%
Hyperlipidaemia (presence of excess lipids in the blood): 8 people, 20.51%
Chest Pain: 8 people, 20.51%
Glaucoma (increased fluid pressure in the eye with vision loss): 8 people, 20.51%
Blood Potassium Decreased: 8 people, 20.51%
Restless Leg Syndrome (a powerful urge to move your legs): 6 people, 15.38%

* Approximation only. Some reports may have incomplete information.

Do you take Tenormin and Jakafi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously